{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-135602","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.799290+00:00","generated_at":"2026-05-29T04:05:00.471177+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Trevi Therapeutics reports positive SSRE for Phase 2b CORAL trial; sample size unchanged at 160 patients.","bullets":["SSRE analysis on highest 108mg BID dose after 80 patients completed 6 weeks recommended continuing as planned; no sample size increase or futility.","Trial enrollment 75% complete; topline results from CORAL Phase 2b still expected in first half of 2025.","Pre-specified conditional power maintained at 80% or greater based on SSRE outcome.","Other two pre-specified SSRE outcomes (sample size increase or futility) were ruled out."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-135602","json":"https://secwatch.observer/filing/0000950170-24-135602.json","markdown":"https://secwatch.observer/filing/0000950170-24-135602.md","text":"https://secwatch.observer/filing/0000950170-24-135602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024135602/0000950170-24-135602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024135602/trvi-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:05:00.471177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}